Bubs’ FDA update is definitely a positive step, but I don’t think it’s the only catalyst driving the share price higher.
In my view, the market is starting to recognise the broader turnaround story, a rebound in revenues, clear strategic shifts, and the impact of new management making real progress.
When FDA approval comes through later this year, we could easily see another 5c+ added to the share price.
Forecasted positive cash flow this year is another key indicator that momentum is building and the business is on the right track
Bubs’ FDA update is definitely a positive step, but I don’t...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
-0.005(2.86%) |
Mkt cap ! $151.8M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.5¢ | 17.0¢ | $82.49K | 485.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 382111 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 609003 | 11 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| BUB (ASX) Chart |